2025/11/17
ZMDD2025 第11回ゼブラフィッシュ・メダカ創薬研究会
2025/10/07
AIプレシジョン患者がん移植ゼブラフィッシュシステムのプロトコル開発
2025/09/05
患者がん移植ゼブラフィッシュモデル(PDXZ)の新しい展開
2025/06/16
患者がん移植ゼブラフィッシュモデル(PDXZ)のFDA受け入れ
2025/04/15
Novel Fluorescent Dye ZMB741 for Podocytopathy Drug Screening
We have discovered stanniocalcin1 as cardiotoxic defence gene in 2015. the potential clinical applications of stanniocalcin in oncocardiology include its use as a biomarker for cancer therapy-induced cardiotoxicity, its potential as a therapeutic target for cardioprotection, and its role in regulating calcium homeostasis, which may be relevant for managing calcium-related cardiovascular complications in cancer patients.